Araceli Biosciences and Ginkgo Bioworks introduce large-scale cell imaging into the Nebula laboratory

Araceli Biosciences and Ginkgo Bioworks ( NYSE : DNA ) announced on Thursday that they have integrated the Endeavor ® high-content imager from Araceli into their autonomous laboratory Nebula located in Boston. Araceli claimed that this Endeavor is the fastest high-content imaging system in the world, capable of bringing real-time analysis cell imaging capabilities into Nebula existing technologies, providing researchers with large, organized datasets necessary for training and validating AI models in drug discovery.

Nebula is built upon Ginkgo's Reconfigurable Automation Carts ( RACs ). Each RAC serves as a modular unit that integrates robotic arms, automatic sample transfer, and unified control software, allowing for the addition or rearrangement of instruments as work processes change. Ginkgo indicates that dozens of scientists use over 100 RAC on Nebula to conduct real research every day, submit experimental procedures, and receive data the following day. Nebula can autonomously and concurrently complete the work of numerous scientists, operating day and night, and occupies approximately one-third of the space required by traditional laboratories.

Endeavor is capable of completing imaging of a 1536-well plate in less than four minutes, and has been integrated into the system based on RAC known as Nebula. It operates in sync with 24/7 experiments. In conjunction with the ClaireRT ™ software from Araceli, Endeavor analyzes each well during image collection. If a well does not meet the preset standards, the system can alert the operator or Nebula, or pause the imaging process to allow for issue resolution before the experiment continues.

Araceli Biosciences President and CEO, Matt Beaudet, stated: "Next-generation drug discovery AI requires a completely different scale of biological data. The laboratories themselves are evolving. They now generate cell data, interpret what they see, and respond in real time. Ginkgo is achieving this through Nebula, while Araceli brings high-content imaging and real-time analysis on a large scale into this closed loop."

Ginkgo Bioworks, co-founder and CEO, and Jason Kelly stated: "With each additional first-class instrument added to an independent laboratory, its value increases. Once one has their own independent laboratory, any scientist can utilize Endeavor's top-tier imaging capabilities and seamlessly integrate them with all other instruments. This is the value of an independent laboratory: combining the best tools in the field of biology with the same software set to conduct experiments 24/7."

Regarding Araceli Biosciences:Araceli Biosciences develops the world's fastest high-content imaging instruments, as well as AI analysis software for automated, AI driven laboratories. Its integrated solutions provide real-time cellular insights, enabling automated workflows to check quality and make decisions at every stage of the experiment, helping biotechnology and pharmaceutical organizations to scale up research and development more quickly and with greater confidence. For more information, please visit aracelibio.com.

Regarding Ginkgo Bioworks:Ginkgo Bioworks is committed to creating tools that make bioengineering more accessible. The company offers autonomous laboratories that replace manual laboratory work with robots, significantly enhancing scientists' productivity. Ginkgo's own autonomous laboratories are also available through research services under contracts with Datapoints and Solutions, provided in the form of "cloud laboratories." For more information, please visit ginkgo.bio, or follow their social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Ginkgo Bioworks develops infrastructure for autonomous laboratories and bio-data generation services, aiming to make experimental science more scalable and accessible. Ginkgo Bioworks is a leading horizontal platform in the field of cell programming, providing flexible end-to-end services to organizations in various markets including food and agriculture, pharmaceuticals, as well as industry and specialty chemicals, to address related challenges.

Ginkgo Bioworks Forward-looking Statement:This announcement contains certain forward-looking statements in the meaning of the federal securities laws, including statements regarding collaboration capabilities and potential success, as well as those concerning Ginkgo's autonomous laboratory. Such forward-looking statements are typically identified by words such as "believes," "can," "expects," "potential," "anticipates," "estimates," "intends," "strategy," "future," "opportunity," "plan," "possible," "should," "will," "shall," "will continue," "is likely to result in," and similar expressions. Forward-looking statements are predictions, speculations, and other statements about future events based on current expectations and assumptions, and therefore involve risks and uncertainties.There are numerous factors that could lead to significant differences between actual future events and the forward-looking statements contained in this announcement, including but not limited to: (i) the company's ability to achieve near-term and long-term cost savings related to the site integration plan, including the ability to terminate leases or find sub-tenants for idle facilities; (ii) volatility in the prices of Ginkgo securities, which is influenced by a variety of factors such as changes in the highly competitive and heavily regulated industries in which they operate and plan to operate, differences in the performance of competitors, and changes in laws and regulations that affect their business; (iii) the ability to execute business plans, forecasts, and other expectations, as well as to identify and realize additional business opportunities, including those related to the solutions and tools business; (iv) the risk of a decline in demand for synthetic biology products; (v) uncertainty in the demand for passive monitoring projects and biosafety services; (vi) changes in the biosafety industry, including technological advancements, the emergence of new competitors, and evolution in industry demand, standards, and regulation; (vii) the outcome of any pending or potential legal proceedings regarding Ginkgo; (viii) the ability to achieve the expected returns and success of platform projects and assets; (ix) the ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables; (x) the success of customers in product development, production, or manufacturing; (xi) the inherent volatility and liquidity risk exposures associated with holding equity in other operating companies and other non-cash consideration that the company may receive for its services; (xii) the potential negative impact of restructuring on the business, or the failure to achieve the expected cost savings; (xiii) uncertainties in government budget priorities and funding allocated to government agencies, including the possible adverse effects of a U.S. government shutdown; (xiv) the ability to expand capacity and continue to develop autonomous laboratories (including Nebula) according to the company's anticipated schedule and extent;( xv ) The speed at which autonomous laboratory infrastructure is being adopted in the broader life sciences and industrial biotechnology markets, and the extent to which it replaces manual laboratory work; ( xvi ) The actual size, composition, and growth of the targetable market that the company is addressing may differ significantly from estimates; ( xvii ) The ability to integrate autonomous laboratory platforms with third-party artificial intelligence models and other technologies, as well as the development and adoption speed of these technologies; ( xviii ) The ability to maintain and expand relationships with strategic partners and customers, including those mentioned in this announcement. The above factors are not exhaustive. Readers should carefully consider these factors, as well as other risks and uncertainties described and discussed in the "Risk Factors" section of Ginkgo's 10-K annual report submitted to the U.S. Securities and Exchange Commission on February 26, 2026, and in other documents submitted from time to time to SEC. These documents list and explain other important risks and uncertainties that could lead to significant differences between actual results and the content contained in forward-looking statements. Forward-looking statements are only valid as of the date they are made. Readers are reminded not to rely too heavily on forward-looking statements, and Ginkgo does not assume nor intend to update or revise these forward-looking statements due to new information, future events, or other reasons. Ginkgo does not guarantee that its expectations will be met.

Araceli Biosciences Investors and Media Contacts:[ email protected ]